Amlodipine gynaecomastia

descriptionPublicationkeyboard_double_arrow_right Article 01 Dec 2001 English Publisher:Elsevier BVJournal:The Breast, volume 10, pages 544-545 (issn: 0960-9776,

Authors: P G, Cornes; A C, Hole;

doi: 10.1054/brst.2001.0308

pmid: 14965638

Amlodipine gynaecomastia

- Summary
- Metrics

Abstract

We report only the second published confirmed case of gynaecomastia caused by amlodipine (a dihydropyridine calcium channel blocker). Gynaecomastia developed in a 70-year-old male within 3 months of starting amlodipine, and symptoms resolved within 3 weeks of drug withdrawal suggesting a strong relationship between amlodipine and gynaecomastia in this patient. Recent research has suggested possible interesting novel mechanisms for amlodipine gynaecomastia, which are discussed.

Related Organizations

Royal Marsden Hospital
United Kingdom

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	13
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average